Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122779 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 2 study of Heart Failure, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT06122779: Recruiting Phase 2 study of Heart Failure, sponsored by Bristol-Myers Squibb.
NCT06122779 is a Phase 2 study of Heart Failure that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 208 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06122779, a Phase 2 study of Heart Failure, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BMS-986435
Study Locations (20)
New York
- Capital Cardiology Associates - Albany
- Local Institution - 0105 - Brooklyn
- Weill Cornell Medicine - New York
- University of Rochester Medical Center - PPDS - Rochester
- Rochester General Hospital Center for Clinical Research - Rochester
- Laurelton Heart Specialist PC - MyClinical - PPDS - Rosedale
Florida
- Ascension St. Vincent's Riverside Hospital - PPDS - Jacksonville
- Local Institution - 0003 - Miami
- University of Miami FL Miller School of Medicine -1120 NW 14th St - Miami
Georgia
- Local Institution - 0014 - Atlanta
- Local Institution - 0048 - Atlanta
Illinois
- Bluhm Cardiovascular Institute of Northwestern - Chicago
- Chicago Medical Research, LLC - Hazel Crest - Hazel Crest
Indiana
- Ascension Medical Group St. Vincent - Indianapolis Heart Care - Indianapolis
- Local Institution - 0045 - Indianapolis
Missouri
- St. Louis Heart and Vascular - St Louis
- Local Institution - 0043 - St Louis
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Colorado Heart and Vascular - Lakewood - Lakewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2026-07-03 |
| Phase | Phase 2 |
What NCT06122779 shows while recruiting
NCT06122779 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06122779 names 20 study sites across 9 states, led by New York, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06122779 about?
NCT06122779 is a clinical study titled "Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)". The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
What is the current status of trial NCT06122779?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2023-11-07. Estimated completion is 2026-07-03.
What conditions does trial NCT06122779 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT06122779?
The interventions under investigation include: Placebo (OTHER), BMS-986435 (DRUG).
Who is sponsoring clinical trial NCT06122779?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122779 being conducted?
This trial has 20 study locations across Alabama, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06122779's enrollment target sits among peer trials
208 161st of 397 higher than 236 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
-
Ertugliflozin in Chronic Heart Failure
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI